JP5600058B2 - メラトニンタブレットならびに調剤及び使用方法 - Google Patents
メラトニンタブレットならびに調剤及び使用方法 Download PDFInfo
- Publication number
- JP5600058B2 JP5600058B2 JP2010503054A JP2010503054A JP5600058B2 JP 5600058 B2 JP5600058 B2 JP 5600058B2 JP 2010503054 A JP2010503054 A JP 2010503054A JP 2010503054 A JP2010503054 A JP 2010503054A JP 5600058 B2 JP5600058 B2 JP 5600058B2
- Authority
- JP
- Japan
- Prior art keywords
- melatonin
- pharmaceutical composition
- pharmaceutically acceptable
- dosage form
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ステップ1:メラトニン及びPEG400を共に混合して、溶液を形成する。
ステップ2:均一化するまで、ステップ1のメラトニンのPEG400溶液にシリカをブレンドして、シリカ担体の混合を形成する。
ステップ3:ステップ2でのシリカ担体の混合を、マンニトール及びグリコール酸デンプンナトリウムに添加し、均一化するまで混合して更なる混合を形成する。
ステップ4:フマール酸ステアリルナトリウムをステップ3での更なる混合に添加し、よく潤滑されるまでブレンドして、潤滑された混合を形成する。
ステップ5:ステップ4での潤滑された混合を1/4インチの回転型押し器を用いて100mgのタブレットに圧縮する。
舌下/バッカルタブレットは、安定性の維持を補助するような方法でパッケージ化できる。パッケージ化する方法及び物質は、限定しないが、ブリスターパッケージ用の箔/箔、箔/アクリロニトリル、箔/ポリクロロトリフルオロエチレン積層におけるブリスターパッケージ、又はガラス及びプラスチックボトルを含むことができる。
ある実施形態では、概日リズム障害及び睡眠障害の治療に有用な、本発明による安定したバイオアベイラビリティを有するメラトニンのバッカル/舌下タブレット製剤の迅速な作用の開始が良く理解される。いくつかの研究はメラトニンが乳癌、線維嚢胞性乳腺疾患、及び結腸癌に有効にもなり得ることを示してきた。メラトニンは免疫、ストレス応答、及び老化プロセス特定の局面を修飾することは示されており、いくつかの研究は睡眠障害、及び、アルツハイマ病の患者の「サンダウニング(sundowning)」の改善を実証した。メラトニンの抗酸化的な役割は、酸化ストレスが病態生理学的プロセスに関連する病状に対し、潜在的に有用でありうる。内在性メラトニン生産は加齢と共に減衰するため、ホルモン補充治療又は栄養補助食品としてのメラトニンの使用が示されている。従って、本発明は上述の治療の総てに有用である。一般的な治療のレジメンは舌下にメラトニンの舌下タブレットを置き、溶解するまで、一般的に5分以内、それを分散しないようにすることによって開始される。これには必要に応じて追加のタブレットが補充されてもよい。この実施形態の用量範囲は、治療のニーズに依存して0.01−3.0mgで相違してもよい。
Claims (11)
- 低いないし乏しい水溶解度を有するメラトニンの舌下又は頬側投与のための固形剤形から成る医薬組成物であって、当該剤形が溶解状態のメラトニンを含み、前記溶解されたメラトニンが薬学的に許容可能な担体と結合し、前記メラトニンが最終的な剤形において溶解状態にあり、
前記溶解されたメラトニンがコーティングされ、吸収され、又は前記担体上へ吸収され、
前記メラトニンが、ポリエチレングリコール、エタノール、イソプロピルアルコール、置換型ポリエチレングリコール、プロピレングリコール、又はその混合物から選択される薬学的に許容可能な溶媒に溶解され、
前記薬学的に許容可能な担体がシリカである、
ことを特徴とする剤形。 - 請求項1に記載の剤形において、前記薬学的に許容可能な溶媒がポリエチレングリコール、または、エタノール、イソプロピルアルコール、またはそれらの混合物とポリエチレングリコールとの混合物であることを特徴とする剤形。
- 請求項1に記載の医薬組成物において、前記薬学的に許容可能な担体が3ないし30ミクロンの大きさの範囲の粒子であることを特徴とする医薬組成物。
- 請求項1に記載の医薬組成物において、前記溶媒中のメラトニンの濃度が5%ないし30% w/wの範囲内にあることを特徴とする医薬組成物。
- 請求項1に記載の医薬組成物において、担体対溶液の重量対重量比が、1:0.5ないし1:4の範囲内にあることを特徴とする医薬組成物。
- 請求項1に記載の医薬組成物が、希釈剤、崩壊剤および潤滑剤を更に含むことを特徴とする医薬組成物。
- 請求項1に記載の医薬組成物が、単位用量につき0.01ないし3mgのメラトニンを含むことを特徴とする医薬組成物。
- 請求項1に記載の医薬組成物が、タブレットの形態であることを特徴とする医薬組成物。
- 請求項1に規定された医薬組成物の調剤方法であって、薬剤溶液を形成するために前記薬学的に許容可能な溶媒中にメラトニンを溶解するステップと、前記薬剤溶液と薬学的に許容可能な担体の粒子とを、コーティングし、吸収し、又は前記溶液を前記担体粒子の上へ吸収するために混合するステップとを含むことを特徴とする方法。
- 請求項9に記載の方法において、前記薬剤溶液が流動性粉末を提供するように更に処理されることを特徴とする方法。
- 請求項9に記載の方法において、当該方法がタブレットを形成するために更なる賦形剤を添加するステップと、前記組成物を圧縮するステップを更に含むことを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92292107P | 2007-04-11 | 2007-04-11 | |
US60/922,921 | 2007-04-11 | ||
PCT/US2008/004615 WO2008127609A1 (en) | 2007-04-11 | 2008-04-10 | Melatonin tablet and methods of preparation and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014164571A Division JP2014237700A (ja) | 2007-04-11 | 2014-08-12 | メラトニンタブレットならびに調剤及び使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010523673A JP2010523673A (ja) | 2010-07-15 |
JP2010523673A5 JP2010523673A5 (ja) | 2013-11-28 |
JP5600058B2 true JP5600058B2 (ja) | 2014-10-01 |
Family
ID=39864239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010503054A Active JP5600058B2 (ja) | 2007-04-11 | 2008-04-10 | メラトニンタブレットならびに調剤及び使用方法 |
JP2014164571A Ceased JP2014237700A (ja) | 2007-04-11 | 2014-08-12 | メラトニンタブレットならびに調剤及び使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014164571A Ceased JP2014237700A (ja) | 2007-04-11 | 2014-08-12 | メラトニンタブレットならびに調剤及び使用方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20100119601A1 (ja) |
EP (2) | EP3056220A1 (ja) |
JP (2) | JP5600058B2 (ja) |
CN (1) | CN101677994B (ja) |
AU (1) | AU2008239683B2 (ja) |
CA (1) | CA2683436C (ja) |
ES (1) | ES2575549T3 (ja) |
IL (2) | IL201383A (ja) |
MX (1) | MX2009010878A (ja) |
RU (1) | RU2485949C2 (ja) |
WO (1) | WO2008127609A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254294B2 (en) | 2003-02-24 | 2016-02-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
US9358296B2 (en) | 2003-02-24 | 2016-06-07 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US10172810B2 (en) * | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
MX2009010878A (es) * | 2007-04-11 | 2010-03-26 | John A Mccarty | Pastilla de melatonina y metodos de preparacion y uso. |
TR200907338A1 (tr) * | 2009-09-28 | 2011-04-21 | Yedi̇tepe Üni̇versi̇tesi̇ | Doğal bileşenler içeren bir film şeridi. |
AR084865A1 (es) | 2011-01-17 | 2013-07-10 | Takeda Pharmaceutical | Preparacion de desintegracion rapida, comprimido dispersable por via oral |
WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
TR201808978T4 (tr) | 2011-02-11 | 2018-07-23 | Zx Pharma Llc | Çok partiküllü l-mentol formülasyonları ve ilgili yöntemler. |
EP2570126B1 (en) | 2011-09-16 | 2014-03-26 | Darius Rassoulian | Use of melatonin for treating acute alcohol intoxication |
ITMI20112042A1 (it) * | 2011-11-10 | 2013-05-11 | Eratech S R L | Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere. |
RU2488388C1 (ru) | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
WO2014175917A1 (en) | 2013-04-23 | 2014-10-30 | Zx Pharma, Llc | Multiparticulate-menthol formulations and related methods |
CA2992923C (en) * | 2014-07-21 | 2021-06-29 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal and sublingual administration of cannabinoids |
CN105663061A (zh) * | 2014-11-16 | 2016-06-15 | 刘佳迪 | 褪黑素滴丸的制法和用法 |
NL2015272B1 (en) * | 2015-08-05 | 2017-05-02 | Versailles B V | Melatonin formulations and methods for preparation and use. |
WO2018167273A1 (en) * | 2017-03-16 | 2018-09-20 | Repoceuticals Aps | Compositions for retarding the decomposition of melatonin in solution |
US10806789B2 (en) * | 2017-05-12 | 2020-10-20 | The LIV Group Inc. | Composition for enhanced absorption of supplements |
US10500280B2 (en) | 2017-06-20 | 2019-12-10 | Physician's Seal, LLC | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
CN109953953B (zh) * | 2017-12-22 | 2021-09-21 | 深圳大学 | 一种褪黑素纳米缓释给药系统的制备方法 |
US20200078307A1 (en) | 2018-03-11 | 2020-03-12 | Nanologica Ab | Porous silica particles for use in a compressed pharmaceutical dosage form |
KR102506059B1 (ko) * | 2020-10-20 | 2023-03-07 | 코스맥스 주식회사 | 멜라토닌을 포함하는 항산화용 화장료 조성물 |
CN112426408B (zh) * | 2020-12-08 | 2023-12-19 | 广州帝奇医药技术有限公司 | 一种褪黑素组合物及其制备工艺 |
CN112870193B (zh) * | 2021-03-11 | 2022-07-08 | 大连医科大学附属第二医院 | 褪黑素在制备治疗对靶向药物耐药的her2阳性乳腺癌的药物中的应用 |
WO2023210811A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210813A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210814A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210812A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 多孔質材料を含む口腔用組成物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
IT1243193B (it) | 1990-08-10 | 1994-05-24 | Medea Res Srl | Composizioni farmaceutiche orali a base di melatonina |
WO1995003043A1 (en) | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US5688520A (en) | 1995-03-29 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Transmucosal delivery of melatonin for prevention of migraine |
FR2742989B1 (fr) * | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
IL127955A0 (en) * | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
US6620836B1 (en) * | 1997-01-22 | 2003-09-16 | Jay Patrick | Antiarrhythmic and tranquilizer composition and treatment |
JP2001518923A (ja) | 1997-03-26 | 2001-10-16 | ダブリュ エイチ エム マーカス,フランシスカス | 鼻腔用メラトニン組成物 |
FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
IT1298731B1 (it) | 1998-03-13 | 2000-02-02 | Recordati Chem Pharm | Composizioni farmaceutiche contenenti complessi di inclusione con melatonina |
JP4080686B2 (ja) * | 2000-11-06 | 2008-04-23 | 株式会社リコー | 画像形成装置 |
KR20010088917A (ko) * | 2001-07-30 | 2001-09-29 | 최종욱 | 디지털 정보 보안 방법 및 그 시스템 |
IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
CN1210026C (zh) * | 2002-10-09 | 2005-07-13 | 重庆太极医药研究院 | 褪黑素双层控释片及制备工艺 |
EP2343045A3 (en) * | 2003-02-24 | 2011-09-21 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
EP1622587B1 (de) * | 2003-05-02 | 2010-04-28 | Globopharm Pharmazeutische Produktions- und Handelsgesellschaft m.b.H. | Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze |
MXPA06003813A (es) * | 2003-10-10 | 2006-06-14 | Lifecycle Pharma As | Forma solida de dosificacion que comprende un fibrato y una estatina. |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
MX2009010878A (es) * | 2007-04-11 | 2010-03-26 | John A Mccarty | Pastilla de melatonina y metodos de preparacion y uso. |
US20140303227A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
-
2008
- 2008-04-10 MX MX2009010878A patent/MX2009010878A/es active IP Right Grant
- 2008-04-10 JP JP2010503054A patent/JP5600058B2/ja active Active
- 2008-04-10 CA CA2683436A patent/CA2683436C/en active Active
- 2008-04-10 AU AU2008239683A patent/AU2008239683B2/en active Active
- 2008-04-10 EP EP16159279.5A patent/EP3056220A1/en not_active Ceased
- 2008-04-10 RU RU2009137472/15A patent/RU2485949C2/ru active
- 2008-04-10 EP EP08742710.0A patent/EP2144610B1/en active Active
- 2008-04-10 ES ES08742710.0T patent/ES2575549T3/es active Active
- 2008-04-10 WO PCT/US2008/004615 patent/WO2008127609A1/en active Application Filing
- 2008-04-10 CN CN200880019163.7A patent/CN101677994B/zh active Active
- 2008-04-10 US US12/595,183 patent/US20100119601A1/en not_active Abandoned
-
2009
- 2009-10-11 IL IL201383A patent/IL201383A/en active IP Right Grant
-
2012
- 2012-10-03 US US13/633,924 patent/US8992948B2/en active Active
-
2014
- 2014-08-12 JP JP2014164571A patent/JP2014237700A/ja not_active Ceased
-
2015
- 2015-02-27 US US14/634,689 patent/US9381190B2/en active Active
-
2016
- 2016-11-21 IL IL249102A patent/IL249102A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20100119601A1 (en) | 2010-05-13 |
IL201383A0 (en) | 2010-05-31 |
JP2014237700A (ja) | 2014-12-18 |
CA2683436A1 (en) | 2008-10-23 |
US9381190B2 (en) | 2016-07-05 |
IL249102A0 (en) | 2017-01-31 |
IL201383A (en) | 2017-01-31 |
CN101677994A (zh) | 2010-03-24 |
AU2008239683B2 (en) | 2014-03-27 |
US20150174101A1 (en) | 2015-06-25 |
EP3056220A1 (en) | 2016-08-17 |
CA2683436C (en) | 2016-07-26 |
EP2144610A1 (en) | 2010-01-20 |
EP2144610A4 (en) | 2013-08-07 |
EP2144610B1 (en) | 2016-04-06 |
JP2010523673A (ja) | 2010-07-15 |
US20130028943A1 (en) | 2013-01-31 |
AU2008239683A1 (en) | 2008-10-23 |
CN101677994B (zh) | 2015-07-22 |
RU2485949C2 (ru) | 2013-06-27 |
ES2575549T3 (es) | 2016-06-29 |
MX2009010878A (es) | 2010-03-26 |
WO2008127609A1 (en) | 2008-10-23 |
US8992948B2 (en) | 2015-03-31 |
RU2009137472A (ru) | 2011-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5600058B2 (ja) | メラトニンタブレットならびに調剤及び使用方法 | |
JP2010523673A5 (ja) | ||
JP6198370B2 (ja) | 経口投与剤形 | |
EP3154529B1 (en) | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use | |
JP4365106B2 (ja) | 医薬配合剤 | |
JP6154803B2 (ja) | 膣投与のための迅速溶解性錠剤組成物 | |
CZ156598A3 (cs) | Použití flurbiprofenu k přípravě léčiva k léčení bolesti v krku | |
JPWO2002096406A1 (ja) | 医薬組成物 | |
KR101400064B1 (ko) | 건식 직타 속붕괴성 정제 | |
JP2007517011A (ja) | 経口デリバリーのための多粒子製剤 | |
TW201350141A (zh) | 速崩散性錠劑 | |
TWI673069B (zh) | 超高速崩解錠劑及其製造方法 | |
TW201636008A (zh) | 超高速崩解錠劑及其製造方法 | |
US20230390244A1 (en) | Modified release compositions comprising melatonin | |
JP2007332063A (ja) | ポビドンヨードを含有する口腔内崩壊型固形製剤 | |
TWI703989B (zh) | 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物 | |
EP2848260B1 (en) | Novel formulations of thiocolchicoside | |
JPH07112936A (ja) | 治療用成分、とくにアスピリンに基づく成分の製剤方法 | |
KR20060123329A (ko) | 월경 곤란증의 예방 및/또는 치료제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110406 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120126 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120314 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130410 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130716 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130806 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130813 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20131009 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140422 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140702 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140723 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140814 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5600058 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |